Bcl-2-related antisense therapy

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 11, 2002, Pages 71-76

  Gutiérrez Puente, Yolanda ^a   Zapata Benavides, Pablo ^a   Tari, Ana M ^a   López Berestein, Gabriel ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE;

APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CONFERENCE PAPER; DRUG SENSITIZATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; LEUKEMIA; LEUKEMIA CELL; LYMPHOMA; LYMPHOMA CELL; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE;

EID: 0036319255     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(02)70129-2     Document Type: Conference Paper

References (65)

1. Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor immune escape
2. Bcl-2 family proteins
3. Subcellular and submitochondrial mode of action of Bcl-2-like proteins
4. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining
5. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/Immunoglobulin transcript resulting from the t(14;18) translocation
6. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
7. Bcl-2 protein in non-small-cell lung carcinoma
8. High prevalence of bcl-2 oncoprotein expression in small cell lung cancer
9. Bcl-2 expression in human melanocytes and melanocytic tumors
10. Human melanocytes and melanoma cells constitutively express the Bcl-2 proto-oncogene in situ and in cell culture
11. Bcl-2 protein expression in melanocytic neoplasms of the skin
12. Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer
13. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy
14. Heterodimerization-independent functions of cell death regulatory proteins Bax and Bcl-2 in yeast and mammalian cell
15. Bak can accelerate chemotherapy-induced cell death independently of its heterodimerization with Bcl-XL and Bcl-2
16. Bcl-2 family proteins - The role of the BH3 domain in apoptosis
17. Bax suppresses tumorigenesis and stimulates apoptosis in vivo
18. Role of bcl-2 in growth factor triggered signal transduction
19. Bcl-2 associates with the ras-related protein R-ras p23
20. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line
21. p53 is required for radiation-induced apoptosis in mouse thymocytes
22. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
23. A negative regulatory element in the bcl-2 5′-untranslated region inhibits expression from an upstream promoter
24. Identification of a p53-dependent negative response element in the bcl-2 gene
25. Tumor suppressor p53 is a direct transcriptional activator of human BAX gene
26. Induction of Bax by genotoxic stress in human cells correlated with normal p53 status and apoptosis
27. Overexpression of the death-promoting gene bax-a which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice
28. Apoptosis-associated signaling pathways are required for chemotherapy-mediated female germ cell destruction
29. Bcl-2 inhibits p53 nuclear import following DNA damage
30. Bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer
31. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer
32. Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA
33. Antisense oligodeoxynucleotides
34. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model
35. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma
36. Bcl-2-mediated tumorigenicity in a human T-lymphoid cell line: Synergy with c-myc and inhibition by Bcl-2 antisense
37. Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: Comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides
38. Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation
39. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins
40. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells
41. Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells
42. The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF4 cells
43. 17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence
44. Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells
45. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7
46. Retinoid receptors: Pathways of proliferation inhibition and apoptosis induction in breast cancer cell lines
47. Progressive resistance to apoptosis in a cell lineage model of human proliferative breast disease
48. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells
49. Differential sensitivity of MCF-7 and LCC2 cells, to multiple growth inhibitory agents: Possible relation to high bcl-2/bax ratio?
50. Interconnections between E2-dependent regulation of cell cycle progression and apoptosis in MCF-7 tumors growing on nude mice
51. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance
52. G(1) phase-dependent expression of bcl-2 mRNA and protein correlates with chemoresistance of human cancer cells
53. Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression
54. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin
55. Bcl-2 protein expression and long-term survival in breast cancer
56. Expression of Bcl-2, but not Bax, correlates with estrogen receptor status and tumor proliferation in invasive breast carcinoma
57. Expression of p53 and bcl-2 in correlation to clinicopathological parameters, hormone receptor status and DNA ploidy in breast cancers
58. Bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group study
59. p53 and bcl-2 expression correlates with clinical outcome in a series of nodepositive breast cancer patients
60. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
61. The Bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients
62. Predictive factors for response to endocrine therapy in patients with recurrent breast cancer
63. Bcl-2 gene family and related proteins in mammary gland involution and breast cancer
64. Bcl-2 expression in normal breast tissue during the menstrual cycle
65. Hormonal regulation of apoptosis in breast cells and tissues